ReviewJournal of clinical medicine2023
The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma (2023).
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Updated Guidelines for the Diagnosis and Treatment of Endometrial Carcinoma: The Polish Society of Gynecological Oncology (2025v).Current oncology (Toronto, Ont.) · 2025Guideline
- Robust graph structure learning to improve multi-omics cancer subtype classification.BMC bioinformatics · 2026Article
- HIF1A, EPAS1, and VEGFA: angiogenesis and hypoxia-related gene expression in endometrium and endometrial epithelial tumors.Journal of applied genetics · 2026Article
- Research trends in depression associated with gynecologic cancers from 2006 to 2025: a multidatabase bibliometric and visual analysis.Frontiers in oncology · 2026Review
- A Machine Learning Approach to Build and Evaluate a Molecular Prognostic Model for Endometrial Cancer Based on Tumour Microenvironment.Journal of cellular and molecular medicine · 2025Article
- Trends in Endometrial Cancer in Poland: Shifts in Clinical Features and Survival Outcomes over 18 Years.Journal of clinical medicine · 2025Article
- Organoid development and applications in gynecological cancers: the new stage of tumor treatment.Journal of nanobiotechnology · 2025Review
- Development and Application of Tumor Organoids: An Emerging Platform for Gynecological Cancers.International journal of women's health · 2025Review
- Robotic-Assisted vs Conventional Laparoscopy for Endometrial Cancer Staging: A Comparative Two-Center Study.Cancer management and research · 2025Article
- Minimally invasive approach is preferred for clinical stage 1 endometrioid-type endometrial cancer.Journal of the Chinese Medical Association : JCMA · 2024Article
- RNA 5-Methylcytosine regulators are associated with cell adhesion and predict prognosis of endometrial cancer.Translational cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to the increasing amount of published data suggesting that endometrial carcinoma is a heterogenic entity with possible different treatment sequences and post-treatment follow-up, the Polish Society of Gynecological Oncology (PSGO) has developed new guidelines.
aimto summarize the current evidence for diagnosis, treatment, and follow-up of endometrial carcinoma and to provide evidence-based recommendations for clinical practice.
methodsThe guidelines have been developed according to standards set by the guideline evaluation tool AGREE II (Appraisal of Guidelines for Research and Evaluation). The strength of scientific evidence has been defined in agreement with The Agency for Health Technology Assessment and Tariff System (AOTMiT) guidelines for scientific evidence classification. The grades of recommendation have been based on the strength of evidence and the level of consensus of the PSGO development group.
conclusionBased on current evidence, both the implementation of the molecular classification of endometrial cancer patients at the beginning of the treatment sequence and the extension of the final postoperative pathological report of additional biomarkers are needed to optimize and improve treatment results as well as to pave the route for future clinical trials on targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.